Non-viral nanoparticles for RNA interference : Principles of design and practical guidelines

Show full item record



Permalink

http://hdl.handle.net/10138/332667

Citation

Liu , Z , Wang , S , Tapeinos , C , Torrieri , G , Känkänen , V , Ibrahim , N E A A , Python , A , Hirvonen , J & Santos , H A 2021 , ' Non-viral nanoparticles for RNA interference : Principles of design and practical guidelines ' , Advanced Drug Delivery Reviews , vol. 174 , pp. 576-612 . https://doi.org/10.1016/j.addr.2021.05.018

Title: Non-viral nanoparticles for RNA interference : Principles of design and practical guidelines
Author: Liu, Zehua; Wang, Shiqi; Tapeinos, Christos; Torrieri, Giulia; Känkänen, Voitto; Ibrahim, Nesma Elsayed Ahmed Ahmed; Python, Andre; Hirvonen, Jouni; Santos, Hélder A.
Contributor: University of Helsinki, Nanomedicines and Biomedical Engineering
University of Helsinki, Nanomedicines and Biomedical Engineering
University of Helsinki, Division of Pharmaceutical Chemistry and Technology
University of Helsinki, Division of Pharmaceutical Chemistry and Technology
University of Helsinki, Nanomedicines and Biomedical Engineering
University of Helsinki, Division of Pharmaceutical Chemistry and Technology
University of Helsinki, Faculty of Pharmacy
University of Helsinki, Divisions of Faculty of Pharmacy
Date: 2021-07
Language: eng
Number of pages: 37
Belongs to series: Advanced Drug Delivery Reviews
ISSN: 0169-409X
URI: http://hdl.handle.net/10138/332667
Abstract: Ribonucleic acid interference (RNAi) is an innovative treatment strategy for a myriad of indications. Non-viral synthetic nanoparticles (NPs) have drawn extensive attention as vectors for RNAi due to their potential advantages, including improved safety, high delivery efficiency and economic feasibility. However, the complex natural process of RNAi and the susceptible nature of oligonucleotides render the NPs subject to particular design principles and requirements for practical fabrication. Here, we summarize the requirements and obstacles for fabricating non-viral nano-vectors for efficient RNAi. To address the delivery challenges, we discuss practical guidelines for materials selection and NP synthesis in order to maximize RNA encapsulation efficiency and protection against degradation, and to facilitate the cytosolic release of oligonucleotides. The current status of clinical translation of RNAi-based therapies and further perspectives for reducing the potential side effects are also reviewed. (c) 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Subject: BUBBLE LIPOSOMES
CELL-PENETRATING PEPTIDE
Clinical translation
ENDOSOMAL ESCAPE
Endosome escape
GENE DELIVERY
IN-VIVO
LIPID NANOPARTICLES
Leukocytes targeting
MEDIATED TARGETED DELIVERY
Non-viral nanoparticles
POLYMER BRUSHES
RNA encapsulation
RNA interference
SIRNA DELIVERY
TUMOR-ASSOCIATED MACROPHAGES
318 Medical biotechnology
221 Nano-technology
317 Pharmacy
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S0169409X21001824_main.pdf 10.20Mb PDF View/Open
Non_viral_nanop ... d_practical_guidelines.pdf 7.991Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record